Close
DeepMind, a tech company owned by Alphabet, is utilizing artificial intelligence to address neglected deadly diseases such as Chagas disease and Leishmaniasis. The company is collaborating with the Drugs for Neglected Diseases initiative (DNDI) to advance treatments for these parasitic diseases. DeepMind's AlphaFold program has shown remarkable accuracy in predicting protein structures in a fraction of the time compared to traditional methods.
The partnership aims to develop new, effective treatments for diseases like cancer, dementia, and infectious diseases by leveraging AI technology. DeepMind's focus on underserved and neglected areas in healthcare highlights the potential impact of AI in accelerating scientific research and drug discovery. The initiative holds promise for providing easier-to-take oral drugs for patients affected by neglected diseases.
Pharmaceutical Technology on MSN.com 11month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
